Profile data is unavailable for this security.
About the company
KALA BIO, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research, development, and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biocfactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing, which is an underlying etiology of multiple severe ocular diseases; KPI-014 specific for inherited retinal degenerative diseases. KPI-012 is in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The Company is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.
- Revenue in USD (TTM)0.00
- Net income in USD-35.84m
- Incorporated2009
- Employees38.00
- LocationKALA BIO Inc1167 Massachusetts AvenueARLINGTON 02476United StatesUSA
- Phone+1 (781) 996-5252
- Fax+1 (781) 642-0399
- Websitehttps://www.kalarx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Immuneering Corp | 0.00 | -62.50m | 322.85m | 54.00 | -- | 1.39 | -- | -- | -1.78 | -1.78 | 0.00 | 3.59 | 0.00 | -- | -- | 0.00 | -40.37 | -46.52 | -42.64 | -49.48 | -- | -- | -- | -4,578.95 | -- | -- | 0.00 | -- | -- | -- | -14.15 | -- | 32.83 | -- |
| Avalo Therapeutics Inc | 192.00k | -99.70m | 326.05m | 23.00 | -- | 3.50 | -- | 1,698.17 | -8.79 | -8.79 | 0.0169 | 5.14 | 0.0017 | -- | -- | 8,347.83 | -89.35 | -94.60 | -128.95 | -128.31 | 54.69 | 81.11 | -52,019.79 | -790.66 | -- | -9.83 | 0.0248 | -- | -77.08 | -42.05 | -11.37 | -- | -- | -- |
| Foghorn Therapeutics Inc | 24.52m | -72.12m | 337.38m | 112.00 | -- | -- | -- | 13.76 | -1.15 | -1.15 | 0.3896 | -1.59 | 0.0955 | -- | -- | 218,910.70 | -28.10 | -28.66 | -38.84 | -33.19 | -- | -- | -294.16 | -596.97 | -- | -- | -- | -- | -33.83 | -- | 11.99 | -- | -1.32 | -- |
| Sutro Biopharma Inc | 105.65m | -216.77m | 337.60m | 178.00 | -- | -- | -- | 3.20 | -25.98 | -25.98 | 12.61 | -10.25 | 0.3194 | -- | 19.98 | 340,793.60 | -65.54 | -31.36 | -94.60 | -37.63 | -- | -- | -205.18 | -152.29 | -- | -- | -- | -- | -59.64 | 7.74 | -112.99 | -- | -2.30 | -- |
| Aldeyra Therapeutics Inc | 0.00 | -43.19m | 338.23m | 9.00 | -- | 6.87 | -- | -- | -0.7217 | -0.7217 | 0.00 | 0.8185 | 0.00 | -- | -- | 0.00 | -44.27 | -34.06 | -57.79 | -38.07 | -- | -- | -- | -- | -- | -- | 0.2359 | -- | -- | -- | -48.77 | -- | -- | -- |
| Northwest Biotherapeutics Inc | 937.00k | -91.22m | 344.72m | 25.00 | -- | -- | -- | 367.90 | -0.0655 | -0.0655 | 0.0007 | -0.0627 | 0.0313 | -- | -- | 37,480.00 | -299.59 | -398.92 | -- | -- | -- | -- | -9,580.90 | -8,255.92 | -- | -6.69 | -- | -- | -28.47 | -10.53 | -32.34 | -- | 23.01 | -- |
| KALA BIO Inc | 0.00 | -35.84m | 353.60m | 38.00 | -- | -- | -- | -- | -5.94 | -5.94 | 0.00 | -1.17 | 0.00 | -- | -- | 0.00 | -90.62 | -61.19 | -316.35 | -75.37 | -- | -- | -- | -1,732.87 | -- | -12.71 | 1.44 | -- | -- | -- | 8.74 | -- | -31.05 | -- |
| Relmada Therapeutics Inc | 0.00 | -56.17m | 354.93m | 17.00 | -- | 16.97 | -- | -- | -1.80 | -1.80 | 0.00 | 0.2852 | 0.00 | -- | -- | 0.00 | -159.13 | -77.37 | -195.99 | -84.69 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 19.04 | -- | -- | -- |
| Monopar Therapeutics Inc | 0.00 | -19.44m | 357.32m | 16.00 | -- | 2.52 | -- | -- | -3.44 | -3.44 | 0.00 | 21.25 | 0.00 | -- | -- | 0.00 | -25.88 | -52.66 | -26.53 | -59.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -85.50 | -- | -- | -- |
| Aclaris Therapeutics Inc | 7.83m | -64.92m | 367.82m | 69.00 | -- | 3.57 | -- | 47.00 | -0.5297 | -0.5297 | 0.0639 | 0.8555 | 0.0411 | -- | 2.66 | 113,420.30 | -34.10 | -44.58 | -40.51 | -50.91 | 6.93 | 39.25 | -829.58 | -491.20 | -- | -- | 0.00 | -- | -58.19 | 3.84 | 50.84 | -- | 15.82 | -- |
| Benitec Biopharma Inc | 0.00 | -46.30m | 370.98m | 19.00 | -- | 1.98 | -- | -- | -1.11 | -1.11 | 0.00 | 5.47 | 0.00 | -- | -- | 0.00 | -34.33 | -79.73 | -35.10 | -88.81 | -- | 88.41 | -- | -53,777.78 | -- | -- | 0.00 | -- | -- | -- | -69.50 | -- | -28.30 | -- |
| Candel Therapeutics Inc | 0.00 | -22.76m | 374.28m | 38.00 | -- | 3.50 | -- | -- | -0.5591 | -0.5591 | 0.00 | 1.46 | 0.00 | -- | -- | 0.00 | -39.54 | -51.34 | -51.19 | -60.61 | -- | -- | -- | -44,190.40 | -- | -- | 0.0609 | -- | -- | -- | -45.44 | -- | -36.83 | -- |
| Greenwich Lifesciences Inc | 0.00 | -19.48m | 379.48m | 4.00 | -- | 172.92 | -- | -- | -1.46 | -1.46 | 0.00 | 0.1584 | 0.00 | -- | -- | 0.00 | -404.39 | -49.65 | -543.43 | -51.94 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.57 | -- | -- | -- |
| Atea Pharmaceuticals Inc | 0.00 | -147.03m | 380.48m | 56.00 | -- | 1.20 | -- | -- | -1.78 | -1.78 | 0.00 | 4.04 | 0.00 | -- | -- | 0.00 | -35.26 | -9.87 | -37.29 | -11.45 | -- | -- | -- | -77.50 | -- | -- | 0.00 | -- | -- | -- | -23.85 | -- | -- | -- |
| Forte Biosciences Inc | 0.00 | -51.74m | 383.95m | 16.00 | -- | 4.56 | -- | -- | -4.49 | -4.49 | 0.00 | 6.71 | 0.00 | -- | -- | 0.00 | -89.96 | -64.69 | -110.72 | -71.52 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.71 | -- | -38.72 | -- |
| Organogenesis Holdings Inc | 564.17m | 15.85m | 385.92m | 854.00 | 32.25 | 1.27 | 11.20 | 0.6841 | 0.093 | 0.093 | 4.30 | 3.42 | 1.03 | 4.93 | 3.45 | 660,619.40 | 6.75 | 6.67 | 8.06 | 8.08 | 75.62 | 75.86 | 6.56 | 6.39 | 3.32 | -- | 0.0487 | 0.00 | 17.04 | 10.77 | 2,236.82 | 3.04 | -4.35 | -- |
Data as of Mar 03 2026. Currency figures normalised to KALA BIO Inc's reporting currency: US Dollar USD
9.51%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baker Bros. Advisors LPas of 31 Dec 2025 | 1.80m | 6.48% |
| Woodline Partners LPas of 31 Dec 2025 | 224.17k | 0.81% |
| Jane Street Capital LLCas of 31 Dec 2025 | 144.35k | 0.52% |
| Adar1 Capital Management LLCas of 31 Dec 2025 | 141.48k | 0.51% |
| Virtu Americas LLCas of 31 Dec 2025 | 85.51k | 0.31% |
| Geode Capital Management LLCas of 31 Dec 2025 | 61.16k | 0.22% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 60.55k | 0.22% |
| Citadel Securities LLCas of 31 Dec 2025 | 56.38k | 0.20% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 40.91k | 0.15% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 29.63k | 0.11% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
